Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib dose escalation after progression on standard-dose sorafenib in advanced renal cell carcinoma
ChiCTR-ONRC-12002088Phase 4Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sorafenib, sunitinib and everolimus in renal cell carcinoma (RCC) (4 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: progression-free survival. Started Apr 2012; status: completed.
02
Drugs
sorafenibsunitinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR-ONRC-12002088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002088.